The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects
2015 · BMC Pharmacology and Toxicology · 63 citations
https://doi.org/10.1186/s40360-015-0017-x
K
Kevin Smart
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
42
Papers
569
Citations
11
h-index
11
i10-index
Kevin Smart is an academic researcher from Roche (Switzerland). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & HER2/EGFR in Cancer Research & Radiopharmaceutical Chemistry and Applications. The author has an h-index of 11, co-authored 36 publications.
Papers by this author
worksEfficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study
2013 · Respiratory Research · 29 citations
https://doi.org/10.1186/1465-9921-14-54
The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers
2014 · European Journal of Drug Metabolism and Pharmacokinetics · 19 citations
https://doi.org/10.1007/s13318-014-0179-8
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025 · Cancer Research Communications · 11 citations
https://doi.org/10.1158/2767-9764.crc-24-0638
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat